Walleye Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Walleye Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.99M	Buy	384,973 +360,768	+1,490%	+$7.84M	0.04%	445
2025 Q4	$509K	Sell	24,205 -273,453	-92%	-$4.77M	﹤0.01%	2953
2025 Q3	$4.58M	Buy	297,658 +71,643	+32%	+$938K	0.02%	978
2025 Q2	$2.12M	Sell	226,015 -101,119	-31%	-$1.11M	0.01%	1469
2025 Q1	$4.02M	Sell	327,134 -37,616	-10%	-$531K	0.02%	935
2024 Q4	$4.82M	Buy	364,750 +326,585	+856%	+$5.59M	0.01%	1100
2024 Q3	$735K	Buy	+38,165	New	+$788K	﹤0.01%	2946
2024 Q1	–	Sell	-127,932	Closed	-$2.76M	–	5864
2023 Q4	$2.76M	Buy	+127,932	New	+$1.97M	0.01%	1538
2023 Q3	–	Sell	-264,464	Closed	-$5.54M	–	5299
2023 Q2	$5.54M	Sell	264,464 -280,626	-51%	-$5.84M	0.02%	669
2023 Q1	$11.5M	Buy	545,090 +213,539	+64%	+$5.31M	0.17%	123
2022 Q4	$8.44M	Buy	+331,551	New	+$7.73M	0.15%	159

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Walleye Capital's SNDX Position: Q1 2026 in Review

Walleye Capital increased its Syndax Pharmaceuticals (SNDX) stake by 1,490% in Q1 2026, buying an estimated $7.84M and bringing the position to 384,973 shares worth $8.99M. The position accounts for 0.04% of the portfolio, ranked #445.

Walleye Capital first reported a position in SNDX in Q4 2022 and has held it in 11 quarters since. The position peaked at $11.5M in Q1 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Walleye Capital held 384,973 shares of Syndax Pharmaceuticals worth $8.99M as of Q1 2026.
Walleye Capital bought 360,768 Syndax Pharmaceuticals shares in Q1 2026, an estimated $7.84M.
Syndax Pharmaceuticals made up 0.04% of Walleye Capital's portfolio in Q1 2026, its #445 holding.
Walleye Capital first reported a position in Syndax Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Walleye Capital's Syndax Pharmaceuticals position peaked at $11.5M in Q1 2023.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.